Why Aurinia’s new Lupkynis trial could change the lupus nephritis treatment sequence
Discover how Aurinia’s PRESERVE study could reshape lupus nephritis care by combining Lupkynis with three major biologic therapies.
Pharma & Biotech
Pharma & Biotech
AstraZeneca gains EU approval for Saphnelo self-injection pen in lupus treatment
AstraZeneca has received European Commission approval for a new subcutaneous formulation of Saphnelo (anifrolumab), allowing adult patients with systemic lupus erythematosus (SLE) to self-administer the drug via a once-weekly pre-filled pen. The regulatory decision follows a positive opinion from the Committee for Medicinal Products for Human Use and is supported by data from the Phase